Handel wiąże się z ryzykiem
Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej.
Handel wiąże się z ryzykiem
Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej.
Design Therapeutics Inc
Closed
3.53 -6.61
Overview
Share price change
24h
Min
3.51
Max
3.77
Income | -4.1M -18M |
|---|---|
EPS | -0.31 |
Employees | 56 |
EBITDA | -3.7M -20M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +115.19% upside |
Next Earnings | 4 sie 2025 |
|---|
Market Cap | -43M 221M |
|---|---|
Previous open | 10.14 |
Previous close | 3.53 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Design Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Design Therapeutics Inc Forecast
Price Target
By TipRanks
115.19% upside
12 Months Forecast
Average 8.5 USD 115.19%
High 12 USD
Low 5 USD
Based on 3 Wall Street analysts offering 12 month price targets forDesign Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Design Therapeutics Inc
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
